Open Access. Powered by Scholars. Published by Universities.®
Acute myeloid leukemia;; recombinant interleukin-2;; phase 3;; immunotherapy;; adjuvant therapy;; ACUTE MYELOGENOUS LEUKEMIA;; NATURAL-KILLER-CELLS;; HIGH-DOSE CYTARABINE;; GROUP-B;; INTENSIFICATION THERAPY;; IN-VIVO;; CANCER;; ADULTS;; SURVIVAL;; TRANSPLANTATION;; Oncology
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Recombinant Interleukin-2 In Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia In First Complete Remission, J. E. Kolitz, S. L. George, D. M. Benson, K. Maharry, G. Marcucci, R. Vij, B. L. Powell, S. L. Allen, D. J. Deangelo, Oncology Alliance Clinical Trials, +8 Additional Authors
Recombinant Interleukin-2 In Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia In First Complete Remission, J. E. Kolitz, S. L. George, D. M. Benson, K. Maharry, G. Marcucci, R. Vij, B. L. Powell, S. L. Allen, D. J. Deangelo, Oncology Alliance Clinical Trials, +8 Additional Authors
Journal Articles
BACKGROUNDRecombinant interleukin-2 (rIL-2) induces cellular cytotoxicity against leukemia blasts. Patients with acute myeloid leukemia (AML) in first complete remission (CR) may harbor minimal residual disease that is susceptible to rIL-2-activated effector cells. METHODSIn the Cancer and Leukemia Group B (CALGB) 19808 study, patients with AML in first CR were randomly assigned after all planned chemotherapy to receive a 90-day course of subcutaneously administered rIL-2 or no further therapy. The primary objective was to compare disease-free survival (DFS) between the 2 treatment arms. A total of 534 patients achieved a CR, 214 of whom were randomized. Six courses of low-dose daily …